A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine

Number of Participants with All-Causality Treatment-emergent Adverse Events (TEAEs)

An AE is any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship with the study intervention. SAE is defined as one of the following: is fatal or life threatening; results in persistent or significant disability/incapacity; constitutes a congenital anomaly/birth defect; is medically significant; requires inpatient hospitalization or prolongation of existing hospitalization. Treatment-emergent AE is defined as an AE with onset date occurring during the on-treatment period. AEs include all SAEs and non-SAEs.

Time frame: TEAE is reported from informed consent up to 28 days after administration of study drug.

Number of participants with clinically significant abnormal vital signs

Vital sign measurements include temperature, respiratory rate, pulse rate, and blood pressure.

Time frame: Assessed from screening up to 6 days after administration of study drug

Number of participants with clinically significant abnormal laboratory findings

Laboratory assessment includes hematology, chemistry and urinalysis. Clinical significance of laboratory abnormalities was judged by investigator.

Time frame: Assessed from screening up to 6 days after administration of study drug

Number of Participants with categorical scores on the Columbia Suicide Severity Rating Scale (C-SSRS)

The C-SSRS is an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. The C-SSRS assessment MUST be performed by an adequately trained, certified, and delegated rater. C-SSRS assessed whether participant experienced any of the following 1: completed suicide, 2: suicide attempt (response of "yes" on "actual attempt"), 3: preparatory acts toward imminent suicidal behavior ("yes" on "aborted attempt", "interrupted attempt", "preparatory acts or behavior"), 4: any suicidal behavior or ideation, suicidal ideation ("yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent"), 7: self-injurious behavior, no suicidal intent ("yes" on "has participant engaged in non-suicidal self-injurious behavior").

Time frame: Assessed from screening up to 6 days after administration of study drug